Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

David Ewing Duncan

A View from David Ewing Duncan

The Great Bio-Divide

At TEDMED - the gap is yawning between hopes and visions and reality in biomedicine

  • October 31, 2011

I was at TEDMED in San Diego last week listening to Stanford physician and entrepreneur Daniel Kraft run through a dizzying array of medical devices, apps, discoveries. They do everything from nano-repairing cells to regenerating damaged tissue in our brains.

Eythor Bender of Berkeley Bionics also talked about exoskeleton technology that is allowing the paralyzed to walk. Catherine Mohr of Intuitive Surgical, Inc. described surgical robots that precisely excise very small tumors.

As Peter Diamandis of the X-Prize said on stage, “we are entering a period of explosive innovation.”

It’s a nascent world of miracles large and small that will be nice when - and if - it happens.

Counterpoised with this brilliant world was a talk the night when TEDMED opened by economist and entrepreneur Juan Enriquez. The world he described - the real world of today’s overpriced, dysfunctional healthcare system - was a dystopic counterpoint to Kraft’s bright and shiny world.

“Our system is operating as an anti-Moore’s Law,” said Enriquez, meaning that innovation in the real world of biomedicine is actually declining. Investments in drugs are in decline as the costs and timelines for developing new meds increases and the number of approved drugs goes down.

Enriquez described cases where drugs were delayed for years by regulatory hurdles, and by an academic environment that is hugely risk adverse. One example: he said a seven year delay in approving beta-blockers resulted in 119,000 deaths of patients that would have benefited from these drugs. And Interleukin-2 was okayed as a treatment for kidney cancer in nine European countries, he noted, but the FDA took 3 1/2 years to grant its approval.

Next year the new owner of TEDMED, Jay Walker, plans to move the meeting to Washington, DC, in part to see if the energy and buzz of excitement over innovation that one often hears about on the west coast can penetrate the dystopia Enriquez described.

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Basic.
  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.